Edition:
United States

GenVec Inc (GNVC.OQ)

GNVC.OQ on NASDAQ Stock Exchange Capital Market

6.31USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$6.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,451
52-wk High
$14.00
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Intrexon Q4 loss per share $0.37
Wednesday, 1 Mar 2017 05:10pm EST 

Intrexon Corp : Intrexon announces fourth quarter and full year 2016 financial results . Q4 revenue $46 million versus i/b/e/s view $52.5 million . Q4 loss per share $0.37 .Q4 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Christopher Brown reports 7.5 pct passive stake in Genvec
Tuesday, 31 Jan 2017 03:32pm EST 

Genvec Inc :Christopher Brown reports 7.5 percent passive stake in Genvec Inc as of January 24 - sec filing.  Full Article

Genvec says will implement one-for-10 reverse stock split - SEC filing
Wednesday, 16 Nov 2016 04:30pm EST 

Genvec Inc : Says on Nov. 16, co announced it will implement a one-for-10 reverse stock split of outstanding shares of common stock - SEC filing .Says trading of co's common stock on Nasdaq Capital Market will begin on a split-adjusted basis at opening of trading on Dec. 1.  Full Article

Genvec says Novartis informed co that it remains engaged on CGF166 program
Thursday, 1 Sep 2016 06:54am EDT 

Genvec Inc : Novartis has informed Genvec that it remains engaged on CGF166 program . Novartis's internal changes are not expected or intended to reduce its support for program Source: (http://bit.ly/2bLXskP ) Further company coverage: [GNVC.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

GenVec Q2 loss per share $0.06
Friday, 5 Aug 2016 07:30am EDT 

GenVec Inc : GenVec reports second quarter 2016 financial results . Q2 loss per share $0.06 . Qtrly revenues $26,000 versus $127,000 .For 2016, GenVec continues to anticipate a cash burn between $6.0 million and $6.5 million.  Full Article

Genvec says FDA lifts hold on clinical trial of hearing loss treatment
Monday, 25 Jul 2016 07:30am EDT 

Genvec Inc :Notified by Novartis that FDA has lifted clinical hold on phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.  Full Article

GenVec reports Q1 loss per share of $0.11
Thursday, 12 May 2016 08:33am EDT 

Genvec Inc : Says believes its existing resources are sufficient to fund operations into 2018 . Says for 2016, GenVec anticipates a cash burn between $6.0 million and $6.5 million . GenVec reports first quarter 2016 financial results . Q1 loss per share $0.11 .Q1 revenue fell 28 percent to $300,000.  Full Article

Sabby Healthcare Master Fund reports 6.02 pct passive stake in Genvec - SEC filing
Friday, 6 May 2016 02:50pm EDT 

Genvec Inc :Sabby Healthcare Master Fund, Ltd reports 6.02 percent passive stake in Genvec Inc as of May 5, 2016 - SEC filing.  Full Article

GenVec and Washington University at St. Louis form collaboration to discover Targeted Adenovector-Based Therapeutics And Vaccines
Wednesday, 3 Jun 2015 08:00am EDT 

GenVec Inc:GenVec, Inc. announces multi-faceted collaboration with Dr. David T. Curiel and his team from the School of Medicine at Washington University at St. Louis (WUSTL).Under the collaboration, GenVec and the WUSTL team will create modified versions of GenVec's gorilla adenovectors that incorporate specialized targeting antibodies on the surface of the vectors.These antibodies are produced only by camels, alpacas and other camelids and are smaller and more stable in intracellular environments than their mouse or human counterparts.The ultimate goal of this collaboration will be to create highly targeted therapeutics and vaccines.  Full Article

GenVec Inc announces collaboration with the Laboratory of Malaria Immunology & Vaccinology
Tuesday, 21 Apr 2015 08:01am EDT 

GenVec Inc:Has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.The research collaboration will utilize GenVec's gorilla adenovirus vectors to deliver a number of antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates.GenVec will construct vaccine candidates at its laboratories and hand them off to LMIV's Vaccine Development Unit.  Full Article

More From Around the Web

BRIEF-Christopher Brown reports 7.5 pct passive stake in Genvec

* Christopher Brown reports 7.5 percent passive stake in Genvec Inc as of January 24 - sec filing Source text : http://bit.ly/2jRXvBb Further company coverage: